Spots Global Cancer Trial Database for Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
Official Title: A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)
Study ID: NCT03410446
Interventions
Study Description
Brief Summary: This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care. The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact Details
Name: Madeline Li, M.D.
Affiliation: Princess Margaret Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
